JPWO2019139869A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019139869A5 JPWO2019139869A5 JP2020538987A JP2020538987A JPWO2019139869A5 JP WO2019139869 A5 JPWO2019139869 A5 JP WO2019139869A5 JP 2020538987 A JP2020538987 A JP 2020538987A JP 2020538987 A JP2020538987 A JP 2020538987A JP WO2019139869 A5 JPWO2019139869 A5 JP WO2019139869A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- hydrogen
- heterocyclyl
- pharmaceutical composition
- aralkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 description 68
- 229910052739 hydrogen Inorganic materials 0.000 description 48
- 239000001257 hydrogen Substances 0.000 description 48
- 238000000034 method Methods 0.000 description 48
- 125000000623 heterocyclic group Chemical group 0.000 description 44
- 239000008194 pharmaceutical composition Substances 0.000 description 41
- 125000003710 aryl alkyl group Chemical group 0.000 description 36
- 125000003118 aryl group Chemical group 0.000 description 36
- 125000001072 heteroaryl group Chemical group 0.000 description 36
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 34
- 150000002431 hydrogen Chemical class 0.000 description 31
- 125000001424 substituent group Chemical group 0.000 description 30
- 125000003545 alkoxy group Chemical group 0.000 description 29
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 description 28
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 28
- 150000001345 alkine derivatives Chemical class 0.000 description 28
- 239000000203 mixture Substances 0.000 description 28
- 125000005843 halogen group Chemical group 0.000 description 26
- 125000004093 cyano group Chemical group *C#N 0.000 description 24
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 17
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 16
- 150000001875 compounds Chemical class 0.000 description 16
- 229910052805 deuterium Inorganic materials 0.000 description 16
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 15
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 12
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 12
- 230000004770 neurodegeneration Effects 0.000 description 10
- 208000015122 neurodegenerative disease Diseases 0.000 description 10
- 239000000651 prodrug Substances 0.000 description 10
- 229940002612 prodrug Drugs 0.000 description 10
- 150000003839 salts Chemical class 0.000 description 10
- 239000012453 solvate Substances 0.000 description 10
- 208000024827 Alzheimer disease Diseases 0.000 description 8
- 125000003342 alkenyl group Chemical group 0.000 description 8
- 125000000304 alkynyl group Chemical group 0.000 description 8
- 125000000753 cycloalkyl group Chemical group 0.000 description 8
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 8
- 125000004433 nitrogen atom Chemical group N* 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 7
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 7
- 239000005711 Benzoic acid Substances 0.000 description 6
- 125000004422 alkyl sulphonamide group Chemical group 0.000 description 6
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 6
- 235000010233 benzoic acid Nutrition 0.000 description 6
- 125000001153 fluoro group Chemical group F* 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 4
- -1 4- (4-cyanophenyl) piperidine-1-carbonyl Chemical group 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000006186 oral dosage form Substances 0.000 description 3
- YPMKPCAILYDVBN-UHFFFAOYSA-N (2-methylphenyl) benzoate Chemical group CC1=CC=CC=C1OC(=O)C1=CC=CC=C1 YPMKPCAILYDVBN-UHFFFAOYSA-N 0.000 description 2
- NWFKBPLDXGCDKS-UHFFFAOYSA-N 3-[(3,5-dimethoxyphenyl)sulfamoyl]benzoic acid Chemical compound COC1=CC(OC)=CC(NS(=O)(=O)C=2C=C(C=CC=2)C(O)=O)=C1 NWFKBPLDXGCDKS-UHFFFAOYSA-N 0.000 description 2
- PQQOVHKHXHTFRM-UHFFFAOYSA-N 4-(2,4-dichlorophenyl)-1-ethyl-2-[(4-phenylphenyl)methyl]imidazole Chemical compound CCN1C=C(N=C1CC2=CC=C(C=C2)C3=CC=CC=C3)C4=C(C=C(C=C4)Cl)Cl PQQOVHKHXHTFRM-UHFFFAOYSA-N 0.000 description 2
- ZRVJBWOTSBBSEB-UHFFFAOYSA-N CC1=C(NS(=O)(=O)C2=CC=CC(=C2)C(O)=O)C=C(C=C1)C(F)(F)F Chemical compound CC1=C(NS(=O)(=O)C2=CC=CC(=C2)C(O)=O)C=C(C=C1)C(F)(F)F ZRVJBWOTSBBSEB-UHFFFAOYSA-N 0.000 description 2
- 108010064397 amyloid beta-protein (1-40) Proteins 0.000 description 2
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 206010044688 Trisomy 21 Diseases 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 239000006207 intravenous dosage form Substances 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023144990A JP2023182589A (ja) | 2018-01-10 | 2023-09-07 | フェニルスルホンアミドを含む薬学的組成物、及びそれらの治療的適用 |
| JP2025165134A JP2026021312A (ja) | 2018-01-10 | 2025-10-01 | フェニルスルホンアミドを含む薬学的組成物、及びそれらの治療的適用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862615869P | 2018-01-10 | 2018-01-10 | |
| US62/615,869 | 2018-01-10 | ||
| PCT/US2019/012608 WO2019139869A1 (en) | 2018-01-10 | 2019-01-08 | Pharmaceutical compositions comprising phenylsulfonamides, and their therapeutic applications |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023144990A Division JP2023182589A (ja) | 2018-01-10 | 2023-09-07 | フェニルスルホンアミドを含む薬学的組成物、及びそれらの治療的適用 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021510168A JP2021510168A (ja) | 2021-04-15 |
| JPWO2019139869A5 true JPWO2019139869A5 (https=) | 2022-01-18 |
| JP2021510168A5 JP2021510168A5 (https=) | 2022-01-18 |
| JP7395480B2 JP7395480B2 (ja) | 2023-12-11 |
Family
ID=65411932
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020538987A Active JP7395480B2 (ja) | 2018-01-10 | 2019-01-08 | フェニルスルホンアミドを含む薬学的組成物、及びそれらの治療的適用 |
| JP2023144990A Pending JP2023182589A (ja) | 2018-01-10 | 2023-09-07 | フェニルスルホンアミドを含む薬学的組成物、及びそれらの治療的適用 |
| JP2025165134A Pending JP2026021312A (ja) | 2018-01-10 | 2025-10-01 | フェニルスルホンアミドを含む薬学的組成物、及びそれらの治療的適用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023144990A Pending JP2023182589A (ja) | 2018-01-10 | 2023-09-07 | フェニルスルホンアミドを含む薬学的組成物、及びそれらの治療的適用 |
| JP2025165134A Pending JP2026021312A (ja) | 2018-01-10 | 2025-10-01 | フェニルスルホンアミドを含む薬学的組成物、及びそれらの治療的適用 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US11701334B2 (https=) |
| EP (1) | EP3737382A1 (https=) |
| JP (3) | JP7395480B2 (https=) |
| AU (2) | AU2019207491A1 (https=) |
| CA (1) | CA3087856A1 (https=) |
| TW (2) | TWI823890B (https=) |
| WO (1) | WO2019139869A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7395480B2 (ja) | 2018-01-10 | 2023-12-11 | クラ セラピューティクス， エルエルシー | フェニルスルホンアミドを含む薬学的組成物、及びそれらの治療的適用 |
| EP3997068A1 (en) * | 2019-07-11 | 2022-05-18 | Cura Therapeutics, LLC | Sulfone compounds and pharmaceutical compositions thereof, and their therapeutic applications for the treatment of neurodegenerative diseases |
| CA3146159A1 (en) * | 2019-07-11 | 2021-01-14 | Cura Therapeutics, Llc | Phenyl compounds and pharmaceutical compositions thereof, and their therapeutic applications |
Family Cites Families (91)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2608506A (en) * | 1949-08-20 | 1952-08-26 | Sharp & Dohme Inc | Arylsulfamyl benzoic acids |
| US3954994A (en) | 1968-10-03 | 1976-05-04 | Pfizer Inc. | Intermediates for preparing hipolipemic agents and method of lowering the blood lipid level in mammals with said agents |
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| US4410545A (en) | 1981-02-13 | 1983-10-18 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| US4328245A (en) | 1981-02-13 | 1982-05-04 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| US4409239A (en) | 1982-01-21 | 1983-10-11 | Syntex (U.S.A.) Inc. | Propylene glycol diester solutions of PGE-type compounds |
| HU196714B (en) | 1984-10-04 | 1989-01-30 | Monsanto Co | Process for producing non-aqueous composition comprising somatotropin |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| US5612059A (en) | 1988-08-30 | 1997-03-18 | Pfizer Inc. | Use of asymmetric membranes in delivery devices |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| PH30995A (en) | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5585112A (en) | 1989-12-22 | 1996-12-17 | Imarx Pharmaceutical Corp. | Method of preparing gas and gaseous precursor-filled microspheres |
| IT1246382B (it) | 1990-04-17 | 1994-11-18 | Eurand Int | Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5543390A (en) | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Covalent microparticle-drug conjugates for biological targeting |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| TW333456B (en) | 1992-12-07 | 1998-06-11 | Takeda Pharm Ind Co Ltd | A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide. |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US6274552B1 (en) | 1993-03-18 | 2001-08-14 | Cytimmune Sciences, Inc. | Composition and method for delivery of biologically-active factors |
| US5523092A (en) | 1993-04-14 | 1996-06-04 | Emory University | Device for local drug delivery and methods for using the same |
| US5985307A (en) | 1993-04-14 | 1999-11-16 | Emory University | Device and method for non-occlusive localized drug delivery |
| US6087324A (en) | 1993-06-24 | 2000-07-11 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| US6004534A (en) | 1993-07-23 | 1999-12-21 | Massachusetts Institute Of Technology | Targeted polymerized liposomes for improved drug delivery |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US5759542A (en) | 1994-08-05 | 1998-06-02 | New England Deaconess Hospital Corporation | Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases |
| US5660854A (en) | 1994-11-28 | 1997-08-26 | Haynes; Duncan H | Drug releasing surgical implant or dressing material |
| US6316652B1 (en) | 1995-06-06 | 2001-11-13 | Kosta Steliou | Drug mitochondrial targeting agents |
| US5798119A (en) | 1995-06-13 | 1998-08-25 | S. C. Johnson & Son, Inc. | Osmotic-delivery devices having vapor-permeable coatings |
| AU6242096A (en) | 1995-06-27 | 1997-01-30 | Takeda Chemical Industries Ltd. | Method of producing sustained-release preparation |
| TW448055B (en) | 1995-09-04 | 2001-08-01 | Takeda Chemical Industries Ltd | Method of production of sustained-release preparation |
| JP2909418B2 (ja) | 1995-09-18 | 1999-06-23 | 株式会社資生堂 | 薬物の遅延放出型マイクロスフイア |
| US6039975A (en) | 1995-10-17 | 2000-03-21 | Hoffman-La Roche Inc. | Colon targeted delivery system |
| US5980945A (en) | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
| TW345603B (en) | 1996-05-29 | 1998-11-21 | Gmundner Fertigteile Gmbh | A noise control device for tracks |
| US6264970B1 (en) | 1996-06-26 | 2001-07-24 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| US6419961B1 (en) | 1996-08-29 | 2002-07-16 | Takeda Chemical Industries, Ltd. | Sustained release microcapsules of a bioactive substance and a biodegradable polymer |
| HUP0000116A3 (en) | 1996-10-01 | 2000-08-28 | Stanford Res Inst Int | Taste-masked microcapsule compositions and methods of manufacture |
| CA2217134A1 (en) | 1996-10-09 | 1998-04-09 | Sumitomo Pharmaceuticals Co., Ltd. | Sustained release formulation |
| DE69730093T2 (de) | 1996-10-31 | 2006-07-20 | Takeda Pharmaceutical Co. Ltd. | Zubereitung mit verzögerter Freisetzung |
| US6131570A (en) | 1998-06-30 | 2000-10-17 | Aradigm Corporation | Temperature controlling device for aerosol drug delivery |
| WO1998027980A2 (en) | 1996-12-20 | 1998-07-02 | Takeda Chemical Industries, Ltd. | Method of producing a sustained-release preparation |
| US5891474A (en) | 1997-01-29 | 1999-04-06 | Poli Industria Chimica, S.P.A. | Time-specific controlled release dosage formulations and method of preparing same |
| US6120751A (en) | 1997-03-21 | 2000-09-19 | Imarx Pharmaceutical Corp. | Charged lipids and uses for the same |
| US6060082A (en) | 1997-04-18 | 2000-05-09 | Massachusetts Institute Of Technology | Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery |
| GB9800750D0 (en) | 1998-01-14 | 1998-03-11 | Lilly Co Eli | Pharmaceutical compound |
| US6350458B1 (en) | 1998-02-10 | 2002-02-26 | Generex Pharmaceuticals Incorporated | Mixed micellar drug deliver system and method of preparation |
| US6613358B2 (en) | 1998-03-18 | 2003-09-02 | Theodore W. Randolph | Sustained-release composition including amorphous polymer |
| US6048736A (en) | 1998-04-29 | 2000-04-11 | Kosak; Kenneth M. | Cyclodextrin polymers for carrying and releasing drugs |
| KR19990085365A (ko) | 1998-05-16 | 1999-12-06 | 허영섭 | 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법 |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| WO2000050391A1 (en) | 1999-02-26 | 2000-08-31 | Merck & Co., Inc. | Novel sulfonamide compounds and uses thereof |
| US6271359B1 (en) | 1999-04-14 | 2001-08-07 | Musc Foundation For Research Development | Tissue-specific and pathogen-specific toxic agents and ribozymes |
| AP2001002264A0 (en) | 2000-08-30 | 2001-09-30 | Pfizer Prod Inc | Sustained release formulations for growth hormone secretagogues. |
| GB0215650D0 (en) | 2002-07-05 | 2002-08-14 | Cyclacel Ltd | Bisarylsufonamide compounds |
| US7279578B2 (en) | 2002-10-11 | 2007-10-09 | Actelion Pharmaceuticals Ltd. | Sulfonylamino-acetic acid derivatives |
| WO2005026134A1 (en) | 2003-09-17 | 2005-03-24 | Novartis Ag | Organic compounds |
| GB0405193D0 (en) | 2004-03-08 | 2004-04-21 | Medical Res Council | Compounds |
| US7262318B2 (en) | 2004-03-10 | 2007-08-28 | Pfizer, Inc. | Substituted heteroaryl- and phenylsulfamoyl compounds |
| US8436006B2 (en) * | 2004-08-06 | 2013-05-07 | Jansssen Pharmaceutica N.V. | 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE) |
| GB0526252D0 (en) * | 2005-12-22 | 2006-02-01 | Novartis Ag | Organic compounds |
| JP4464926B2 (ja) | 2006-01-25 | 2010-05-19 | ニューロテック ファーマシューティカルズ カンパニー リミテッド | 中枢神経系の急性及び慢性的損傷に起因した神経変性を防止するための化合物、組成物及び方法 |
| PE20081581A1 (es) | 2006-12-21 | 2008-11-12 | Plexxikon Inc | COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA |
| EP3085367A3 (en) | 2007-03-20 | 2017-01-25 | Brandeis University | Compositions for the diagnosis, treatment, and prevention of amyotrophic lateral sclerosis and related |
| WO2008129288A2 (en) | 2007-04-19 | 2008-10-30 | Boehringer Ingelheim International Gmbh | Disulfonamides useful in the treatment of inflammation |
| JP2008308493A (ja) | 2007-05-17 | 2008-12-25 | Kissei Pharmaceut Co Ltd | 新規なカテコール誘導体、それを含有する医薬組成物およびそれらの用途 |
| TW201028421A (en) | 2009-01-15 | 2010-08-01 | Abbott Lab | Novel benzenesulfonamides as calcium channel blockers |
| ES2761295T3 (es) | 2009-03-02 | 2020-05-19 | Stemsynergy Therapeutics Inc | Métodos y composiciones para su uso en el tratamiento del cáncer y para reducir los efectos mediados por Wnt en una célula |
| RU2011148937A (ru) | 2009-05-01 | 2013-06-10 | Раквалиа Фарма Инк. | Производные сульфамоилбензойной кислоты в качестве антагонистов trpm8 |
| TW201041888A (en) * | 2009-05-06 | 2010-12-01 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| JP6038792B2 (ja) | 2010-09-03 | 2016-12-07 | フォーマ ティーエム， エルエルシー． | 癌などの疾患の治療のためのｎａｍｐｔ阻害剤としての４−｛［（ピリジン−３−イル−メチル）アミノカルボニル］アミノ｝ベンゼン−スルホン誘導体 |
| EP2780321B1 (en) * | 2011-10-10 | 2015-12-30 | Astrazeneca AB | Mono-fluoro beta-secretase inhibitors |
| CN104211666B (zh) | 2013-05-31 | 2017-11-14 | 中国人民解放军军事医学科学院毒物药物研究所 | 2,3‑环氧丁二酰胺类化合物、其制备方法和用途 |
| CA2969756A1 (en) * | 2014-12-05 | 2016-06-09 | Aquinnah Pharmaceuticals, Inc. | Sulfonamide derivatives, compositions and methods of use in the treatment of neurodegenerative diseases |
| US20180071238A1 (en) * | 2015-04-10 | 2018-03-15 | Ohio University | Compositions and Methods for Traumatized Tissues Using Zinc Chelators |
| US10858316B2 (en) | 2015-07-10 | 2020-12-08 | University Of Maryland, Baltimore | Small molecule inhibitors of the MCL-1 oncoprotein and uses thereof |
| WO2017160069A1 (ko) | 2016-03-15 | 2017-09-21 | 재단법인 의약바이오컨버젼스연구단 | 신규한 벤젠설폰아미드 유도체 및 이의 용도 |
| CN109081818B (zh) | 2017-06-14 | 2022-04-22 | 南京华威医药科技集团有限公司 | 新型吲哚胺2,3-双加氧化酶抑制剂 |
| CN109651208B (zh) | 2017-10-10 | 2022-01-04 | 中国科学院上海药物研究所 | N-芳基磺酰胺类化合物，其药物组合物及其用途 |
| JP7395480B2 (ja) * | 2018-01-10 | 2023-12-11 | クラ セラピューティクス， エルエルシー | フェニルスルホンアミドを含む薬学的組成物、及びそれらの治療的適用 |
| CN109293537A (zh) | 2018-11-12 | 2019-02-01 | 中国药科大学 | 磺酰胺类化合物及其医药用途 |
| CA3146159A1 (en) * | 2019-07-11 | 2021-01-14 | Cura Therapeutics, Llc | Phenyl compounds and pharmaceutical compositions thereof, and their therapeutic applications |
| EP3997068A1 (en) | 2019-07-11 | 2022-05-18 | Cura Therapeutics, LLC | Sulfone compounds and pharmaceutical compositions thereof, and their therapeutic applications for the treatment of neurodegenerative diseases |
-
2019
- 2019-01-08 JP JP2020538987A patent/JP7395480B2/ja active Active
- 2019-01-08 CA CA3087856A patent/CA3087856A1/en active Pending
- 2019-01-08 TW TW108100722A patent/TWI823890B/zh active
- 2019-01-08 WO PCT/US2019/012608 patent/WO2019139869A1/en not_active Ceased
- 2019-01-08 TW TW112141994A patent/TW202406538A/zh unknown
- 2019-01-08 EP EP19705255.8A patent/EP3737382A1/en active Pending
- 2019-01-08 US US16/961,191 patent/US11701334B2/en active Active
- 2019-01-08 AU AU2019207491A patent/AU2019207491A1/en not_active Abandoned
-
2023
- 2023-06-02 US US18/205,283 patent/US20240016768A1/en not_active Abandoned
- 2023-09-07 JP JP2023144990A patent/JP2023182589A/ja active Pending
-
2024
- 2024-08-28 US US18/817,959 patent/US20250177334A1/en active Pending
- 2024-11-07 AU AU2024259810A patent/AU2024259810A1/en active Pending
-
2025
- 2025-10-01 JP JP2025165134A patent/JP2026021312A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7605892B2 (ja) | Ｔｅａｄ転写因子の新規小分子阻害剤 | |
| JP2014509647A5 (https=) | ||
| RU2005128190A (ru) | Ингибиторы фактора подавления миграции макрофагов (фпм) и способы их идентификации | |
| RU2011101774A (ru) | Новые замещенные пиридин-2-оны и пиридазин-3-оны | |
| RU2003105805A (ru) | Производные 4-фенилпиридина в качестве антагонистов рецепторов нейрокинина-1 | |
| JP2011509309A5 (https=) | ||
| JP6039549B2 (ja) | 化学療法または放射線療法によって誘発される嘔吐を予防および／または治療するためのシグマリガンド | |
| JP2016534134A5 (https=) | ||
| JPWO2020061101A5 (https=) | ||
| RU2011134634A (ru) | Индуцирующие апоптоз средства для лечения рака и иммунных и аутоиммунных заболеваний | |
| JP2005534635A5 (https=) | ||
| JPWO2020190774A5 (https=) | ||
| JP2017504576A5 (https=) | ||
| JP2017214387A5 (https=) | ||
| RU2010123796A (ru) | Способ лечения артрита | |
| RU2014141674A (ru) | 3,5-диаминопиразоловые ингибиторы киназы | |
| JP2021510168A5 (https=) | ||
| JP2013528619A5 (https=) | ||
| JP2007514691A5 (https=) | ||
| JP2023511146A (ja) | イソインドリン誘導体、並びにその医薬組成物及び使用 | |
| JP2013522316A5 (https=) | ||
| KR101422299B1 (ko) | (2ｒ)-2-〔(4-설포닐)아미노페닐〕프로판아마이드 및 이들 화합물을 함유하는 약학 조성물 | |
| JP2020504122A5 (https=) | ||
| JP2008542365A5 (https=) | ||
| JP2019515017A5 (https=) |